Study to Assess an Interphase Cycle With Flotetuzumab.

NCT05063123 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Withdrawal of MacroGenics (pharmaceutical company)

Conditions

AML

Interventions

DRUG: Flotetuzumab

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland